Bristol-Myers Squibb ASCO GU 2024 AR LDD Phase 1

Bristol-Myers Squibb presented Phase 1 clinical data for AR LDD, a targeted protein degradation therapeutic for metastatic castration-resistant prostate cancer. The compound demonstrated promising efficacy and durability across multiple AR statuses in heavily pretreated patients with a manageable safety profile.